Join us as we explore Axon, a company at the forefront of law enforcement technology. With strong ratings from our analysts, find out if this stock is a hidden gem worth your investment.
Cineverse (NASDAQ:CNVS) reported first-quarter fiscal 2027 revenue growth of 175% as the company integrated its Giant Worldwide and IndiCue acquisitions, while management reaffirmed full-year guidance and outlined plans for cost reductions, platform automation and new advertising products.
Revenue
CapsoVision (NASDAQ:CV) reported second-quarter revenue growth as sales of its CapsoCam Plus capsule endoscopy system increased, while the company advanced its artificial intelligence software rollout and development programs for colon and upper gastrointestinal applications.
Revenue for the second
EZCORP (NASDAQ:EZPW) Chief Financial Officer Tim Jugmans said the pawn retailer’s latest quarterly results reflected both favorable consumer conditions and operational improvements, including store expansion, pricing discipline and acquisitions.
Speaking at Canaccord’s 46th Annual Growth Conference
Blaize (NASDAQ:BZAI) lowered its full-year 2026 revenue outlook to $40 million to $43 million, from prior guidance of $130 million, citing delayed customer deployments, commercial opportunities that did not convert as expected, higher memory costs and a provision tied to an outstanding Starshine rec
Capricor Therapeutics (NASDAQ:CAPR) said its biologics license application for deramiocel remains under U.S. Food and Drug Administration review, while the company prepares to submit an amendment seeking a refined indication centered on upper limb skeletal muscle function in Duchenne muscular dystro
Cibus (NASDAQ:CBUS) reported second-quarter 2026 revenue of $1.0 million, compared with $0.9 million a year earlier, as the agricultural biotechnology company advanced its Sustainable Ingredients program and updated the expected timing of its initial rice launch in Latin America.
For the first six
Celcuity (NASDAQ:CELC) said it remains on track to begin commercial shipments of REVTORPYK, its gedatolisib therapy for certain patients with advanced breast cancer, late in the third quarter of 2026 following its recent FDA approval.
The FDA approved REVTORPYK in July in combination with fulvestra
AmpliTech Group (NASDAQ:AMPG) reported second-quarter 2026 revenue of approximately $8.1 million, up 51% sequentially from about $5.35 million in the first quarter, as the company continued to invest in 5G, telecom infrastructure, semiconductor and advanced communications opportunities.
Management
